Reports Q4 revenue $3.7, consensus $3.78. “2023 was a transformational year for Kenvue as we began delivering on our long-term value creation algorithm centered around profitable growth, durable cash flow generation and disciplined capital allocation,” said Thibaut Mongon, CEO. “We enter 2024 with clear strategic priorities as an independent Kenvue, including strengthened plans in our U.S. Skin Health and Beauty business. Looking ahead we’re focused on reaching more consumers, reinventing our ways of working to invest more in our brands, and fostering a culture that rewards performance and impact in our organization.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KVUE:
- Madrigal Pharmaceuticals announces additions to leadership team
- The beauty and wellness stocks to own in 2024, according to Piper Sandler
- Kenvue price target raised to $22 from $20 at Piper Sandler
- Kenvue Inc put volume heavy and directionally bearish
- Johnson & Johnson Stock (NYSE:JNJ): A Smart Dividend Pick for 2024